Robust by Design: Addressing New Challenges in Bulk Drug Substance Management

Thank you - Your Download is Available Below

Robust by Design: Addressing New Challenges in Bulk Drug Substance Management

PDF | 1.1 MB

Robust by Design: Addressing New Challenges in Bulk Drug Substance Management

Over 95% of all approved biologics and 90% of all vaccines are cold chain dependent. However, up to 25% of vaccines are believed to be lost due to cold chain failures. Modern cold chains should be supported by highly robust freezing solutions to meet new demands and help prevent losses.

This whitepaper discusses the philosophy of "robust by design” freezing containers based on characterization knowledge, design experience, and an understanding of real-world freezing applications.

Clear form data

Please Complete the Form

First Name *

Last Name *

E-Mail *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Thank you - Your Download is Available Below

Robust by Design: Addressing New Challenges in Bulk Drug Substance Management

Robust by Design: Addressing New Challenges in Bulk Drug Substance Management

Please Complete the Form

Complete Form to Access the File